Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Gallagher Re, a reinsurance brokerage and risk management services provider, has released a report on the impact of GLP-1 ...

As the indications and demand for glucagon-like peptide-1 (GLP-1) agonist drugs continue to expand, the real-world GLP-1 research and data-driven insights from Prime Therapeutics LLC (Prime) help ...

According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...

Allurion Announces Initial Results on the Combination of the Allurion Program With Low-dose GLP-1 Therapy to Optimize Muscle Mass and GLP-1 Adherence Average Total Weight Loss of 20% With 15% ...

Many employers are facing challenges in incorporating high-cost GLP-1 medications, such as Mounjaro, Ozempic, Rybelsus, Trulicity, and Wegovy, ...

Skinny jab? Try skinny juice. For centuries, it’s been enjoyed by people in South America — and it’s long been linked to ...

Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose GLP-1 therapy to optimize ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, ...